ou are invited to attend the Annual Meeting of Shareholders of Johnson & Johnson. Due to ongoing public health concerns regarding the COVID-19 pandemic and for the health and well-being of our shareholders, directors, management and associates, the 2021 Annual Meeting will be held online in a virtual format.
Shareholders as of the record date may attend, vote and submit questions virtually at our Annual Meeting by logging in at www.proxyvote.com/JNJ. To log in, shareholders (or their authorized representatives) will need the 16-digit control number provided on your notice, on your proxy card or in the voting instructions that accompanied your proxy materials. On the day of the meeting shareholders should log into the virtual meeting url: www.virtualshareholdermeeting.com/JNJ2021.
As of this date, a state of emergency is in effect in the State of New Jersey relating to the COVID-19 pandemic. Johnson & Johnson is permitted to hold a virtual meeting of shareholders under New Jersey law so long as a state of emergency remains in effect. In the event that the state of emergency is lifted prior to the date fixed for the 2021 Annual Meeting, and it is not, therefore, then legally permissible to hold a completely virtual annual meeting under New Jersey law, we will announce alternative arrangements for the 2021 Annual Meeting as promptly as practicable. Any such change will be announced via press release and website posting, as well as the filing of additional Proxy materials with the Securities and Exchange Commission.
Mary C. Beckerle, Ph.D.
Chief Executive Officer, Huntsman Cancer Institute at the University of Utah; Distinguished Professor of Biology and Oncological Sciences, University of Utah
Ian E. L. Davis
Non-Executive Chairman, Rolls-Royce Holdings plc; Former Chairman and Worldwide Managing Director, McKinsey & Company
Jennifer A. Doudna, Ph.D.
Professor of Chemistry; Professor of Biochemistry & Molecular Biology; Li Ka Shing Chancellor's Professorship in Biomedical and Health, University of California, Berkeley
Marillyn A. Hewson
Former Chairman, President and Chief Executive Officer, Lockheed Martin Corporation
Mark B. McClellan, M.D., Ph.D.
Director, Duke-Robert J. Margolis, MD, Center for Health Policy; Margolis Professor of Business Medicine and Policy, Duke University
A. Eugene Washington, M.D., M.Sc.
Duke University’s Chancellor for Health Affairs; President and Chief Executive Officer, Duke University Health System
Nadja Y. West, M.D.
Retired United States Army Lieutenant General and Former United States Army Surgeon General